Sermorelin (GRF 1-29) is the shortest fully functional fragment of growth hormone-releasing hormone, containing the first 29 amino acids of the native 44-amino-acid peptide. It is one of the most extensively studied GHRH analogs in endocrine research with decades of published literature.
Structure and Pharmacology
Native human GHRH is a 44-amino-acid peptide, but research established that the full biological activity resides in the first 29 residues. Sermorelin (Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2) retains full agonist activity at the GHRH receptor while being more practical to synthesize than the full-length peptide. It binds to the GHRH receptor (GHRHR) on pituitary somatotroph cells, activating adenylyl cyclase through Gs protein coupling, which increases intracellular cAMP and stimulates GH gene transcription, synthesis, and secretion.
The half-life of sermorelin is approximately 10–20 minutes due to rapid proteolytic cleavage, primarily by DPP-IV at the Ala2-Asp3 bond. This short half-life produces acute, pulsatile GH release that closely mimics physiological GHRH signaling. Modified analogs like CJC-1295 were subsequently developed with amino acid substitutions at the DPP-IV cleavage site to extend the duration of action.
Key Research Findings
Sermorelin has been used in hundreds of published research studies examining GH axis physiology. As a diagnostic tool, sermorelin stimulation testing helps assess pituitary GH reserve — a normal GH response to sermorelin confirms intact somatotroph function and suggests that GH deficiency originates at the hypothalamic level. In preclinical research, sermorelin has been used to study age-related GH decline (somatopause), demonstrating that the pituitary retains the capacity to release GH in aged models when stimulated by exogenous GHRH, even though endogenous GHRH signaling diminishes.
Research has also examined sermorelin’s effects on sleep architecture, showing that GHRH signaling is closely linked to slow-wave sleep. Administration of sermorelin in preclinical models enhanced slow-wave sleep duration and GH pulse amplitude during sleep, supporting the physiological connection between the somatotropic axis and sleep regulation.
Sermorelin vs Other GHRH Analogs
Compared to CJC-1295, sermorelin has a shorter half-life and produces more discrete GH pulses. This makes sermorelin better suited for studies of acute GH responses and pulsatility, while CJC-1295 is preferred for sustained GH elevation. Compared to tesamorelin (a synthetic GHRH analog with a trans-3-hexenoic acid modification), sermorelin has broader research applications because tesamorelin’s published literature focuses more narrowly on visceral adiposity. Sermorelin remains the reference GHRH analog against which newer compounds are benchmarked in receptor binding and GH release assays.
Frequently Asked Questions
Why is sermorelin called GRF 1-29?
GRF stands for Growth hormone-Releasing Factor, an earlier name for GHRH. The “1-29” indicates it contains amino acids 1 through 29 of the full 44-amino-acid sequence. This nomenclature persists in research literature alongside the name “sermorelin,” which was assigned as the compound’s International Nonproprietary Name (INN) for standardized identification.
How does sermorelin differ from exogenous GH in research?
Sermorelin stimulates the pituitary to release endogenous GH in a pulsatile, physiologically regulated manner. The resulting GH release is subject to normal negative feedback from IGF-1 and somatostatin. Exogenous GH bypasses the pituitary entirely, producing sustained supraphysiological levels that suppress endogenous GH secretion. Sermorelin studies therefore model augmented physiological signaling, while exogenous GH studies model pharmacological replacement.